Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bipolar Disorder II Clear all
Withdrawn Phase 2 Interventional

Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence

NCT00204503
View directory record Official record
Conditions
Bipolar I or II Depression and Alcohol Abuse or Dependence
Interventions
Depakote ER
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 21, 2026, 3:32 AM EDT
Recruiting Phase 4 Interventional

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 4 Interventional

Antidepressant Therapy for Bipolar II Major Depression

NCT00641927
View directory record Official record
Conditions
Bipolar Type II Disorder
Interventions
Venlafaxine, Lithium Carbonate
Drug
Lead sponsor
Stanley Medical Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 21, 2026, 3:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ginger.io Behavioral Health Study

NCT02491307
View directory record Official record
Conditions
Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Ginger.io Smartphone Application
Other
Lead sponsor
Community Health Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
4
States / cities
Meriden, Connecticut • Middletown, Connecticut • New Britain, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder

NCT05340504
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder
Interventions
N-Acetyl cysteine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 21, 2026, 3:32 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

NCT07220460
View directory record Official record
Conditions
Bipolar I or II Disorder
Interventions
ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Anaheim, California • Colton, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

NCT02090114
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

NCT03249376
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lumateperone, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Sherman Oaks, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Sertraline, Lithium carbonate
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 21, 2026, 3:32 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

NCT04211428
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Bipolar Type I Disorder, Bipolar Disorder Mild, Bipolar Disorder Moderate, Bipolar Disorder Severe
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 21, 2026, 3:32 AM EDT
Withdrawn Phase 4 Interventional

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

NCT01932541
View directory record Official record
Conditions
Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder, Bipolar Disorder
Interventions
Latuda (Lurasidone)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Results available

Tranylcypromine Treatment of Bipolar Depression

NCT01430455
View directory record Official record
Conditions
Bipolar Disorder I or II
Interventions
Tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 21, 2026, 3:32 AM EDT
Completed No phase listed Observational

Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

NCT02220309
View directory record Official record
Conditions
Anxiety, Depression
Interventions
Pramipexole Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
3
States / cities
Los Altos, California • Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

FOCUS Bipolar: Families Opening Conversations for Understanding Signs

NCT07622927
View directory record Official record
Conditions
Bipolar Disorder (BD), Bipolar Disorder I or II, Bipolar Disorder Family Members, Screening Tool
Interventions
Co-design Workshop (Observational Procedure), Alpha Testing (Observational Procedure), Beta Testing (Observational Procedure), Youth Screening Pathway & Brief Follow-Up Interview (Observational Procedure)
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids

NCT01841970
View directory record Official record
Conditions
Hemorrhoids, Internal
Interventions
HET Bipolar System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

NCT07116694
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
Interventions
BXCL501 Sublingual Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Chino, California • Oceanside, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Active, not recruiting Not applicable Interventional

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

NCT05849402
View directory record Official record
Conditions
Bipolar II Disorder, Most Recent Episode Major Depressive, Current Depressive Episode, Treatment Resistant Depression
Interventions
Active Comparator: Active aiTBS, Sham Comparator: Sham aiTBS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Results available

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

NCT03156504
View directory record Official record
Conditions
Major Depression, Bipolar I Disorder, Bipolar II Disorder, Unipolar Depression
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 21, 2026, 3:32 AM EDT
Withdrawn Phase 2 Interventional

rTMS for Treatment of Depressed Phase of Bipolar Disorder Type II

NCT00447096
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder

NCT01909011
View directory record Official record
Conditions
Bi-polar II Disorder
Interventions
Active CES, Sham CES
Device
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Sensoril(Ashwaganhda)for Bipolar Disorder

NCT00761761
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Bipolar Disorder NOS
Interventions
Sensoril, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 21, 2026, 3:32 AM EDT
Not listed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

NCT04285515
View directory record Official record
Conditions
Bipolar Depression, Major Depressive Disorder
Interventions
Lumateperone, Placebos
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Garden Grove, California • Oceanside, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

NCT06605599
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Dothan, Alabama • Anaheim, California • Colton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 3:32 AM EDT